Navidea Biopharmaceuticals Inc. (NAVB)

0.73
0.02 2.82
AMEX : Health Technology
Prev Close 0.71
Open 0.70
Day Low/High 0.70 / 0.73
52 Wk Low/High 0.14 / 7.39
Volume 1.40K
Avg Volume 107.60K
Exchange AMEX
Shares Outstanding 18.06M
Market Cap 12.64M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results

Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter of 2019.

Navidea Biopharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Thursday,...

Navidea Biopharmaceuticals Announces SNMMI Press Release And Recognition Of Phase 1/2 Study Results

Navidea Biopharmaceuticals Announces SNMMI Press Release And Recognition Of Phase 1/2 Study Results

Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the results of the Company's NAV3-21 clinical...

Navidea Biopharmaceuticals Announces Closing Of Public Offering Of Common Stock

Navidea Biopharmaceuticals Announces Closing Of Public Offering Of Common Stock

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the closing of an underwritten public offering of...

Navidea Biopharmaceuticals Announces Day And Time Of SNMMI Presentation Of Phase 1/2 Study Results And Enrollment Update On Its Phase 2B Study

Navidea Biopharmaceuticals Announces Day And Time Of SNMMI Presentation Of Phase 1/2 Study Results And Enrollment Update On Its Phase 2B Study

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce the details of an oral presentation on the...

Navidea Biopharmaceuticals Prices $6.0 Million Public Offering Of Common Stock

Navidea Biopharmaceuticals Prices $6.0 Million Public Offering Of Common Stock

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the pricing of its previously announced underwritten...

Navidea Biopharmaceuticals Announces Proposed Public Offering Of Common Stock

Navidea Biopharmaceuticals Announces Proposed Public Offering Of Common Stock

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it intends to offer and sell shares of its common...

Navidea Biopharmaceuticals Regains Direct Control Of Intellectual Property

Navidea Biopharmaceuticals Regains Direct Control Of Intellectual Property

On June 12, 2019, Vice Chancellor Joseph Slights of the Court of Chancery of the State of Delaware issued an oral ruling granting the motion of Macrophage Therapeutics, Inc.

Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results

Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter of 2019.

Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday,...

Navidea Biopharmaceuticals Announces Comparative Study To Evaluate The Potential Utility Of Tilmanocept In Patients With Tuberculosis ("TB")

Navidea Biopharmaceuticals Announces Comparative Study To Evaluate The Potential Utility Of Tilmanocept In Patients With Tuberculosis ("TB")

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Professor Mike Sathekge, MBChB, M.

Navidea Biopharmaceuticals Announces Reverse Stock Split

Navidea Biopharmaceuticals Announces Reverse Stock Split

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has approved a...

Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design And Provides Business Updates

Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design And Provides Business Updates

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received feedback from the U.

Navidea Biopharmaceuticals Data To Be Presented At Society Of Nuclear Medicine And Molecular Imaging Annual Meeting

Navidea Biopharmaceuticals Data To Be Presented At Society Of Nuclear Medicine And Molecular Imaging Annual Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Arash Kardan, M.

Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates

Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced execution of a Stock Purchase Agreement (the "Purchase...

Navidea Biopharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results

Navidea Biopharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full...

Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Thursday, March 7 th,...

Navidea Biopharmaceuticals Announces Extension Of NYSE American Listing

Navidea Biopharmaceuticals Announces Extension Of NYSE American Listing

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the receipt of a notice from the NYSE American LLC (the...

Navidea Biopharmaceuticals Announces Decision By Ohio Supreme Court

Navidea Biopharmaceuticals Announces Decision By Ohio Supreme Court

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition...

Navidea Biopharmaceuticals Announces Patent Extension For Lymphoseek®

Navidea Biopharmaceuticals Announces Patent Extension For Lymphoseek®

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 23, 2018 the U.

Navidea Biopharmaceuticals Appoints Adam Cutler To Board Of Directors

Navidea Biopharmaceuticals Appoints Adam Cutler To Board Of Directors

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Adam Cutler to the Company's board of...

Navidea Biopharmaceuticals Appoints Dr. Michael Rosol As Chief Medical Officer

Navidea Biopharmaceuticals Appoints Dr. Michael Rosol As Chief Medical Officer

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Michael Rosol, PhD as Chief Medical...

Navidea Biopharmaceuticals To Present At The 11th Annual LD Micro Event 2018

Navidea Biopharmaceuticals To Present At The 11th Annual LD Micro Event 2018

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Chief Executive Officer, Jed Latkin, will...

Navidea Biopharmaceuticals Announces Presentation At The Radiological Society Of North America (RSNA) 104th Scientific Assembly And Annual Meeting 2018

Navidea Biopharmaceuticals Announces Presentation At The Radiological Society Of North America (RSNA) 104th Scientific Assembly And Annual Meeting 2018

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Dr.

Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan To Board Of Directors

Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan To Board Of Directors

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Kathy Rouan, PhD, to the Company's...

Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results

Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter of 2018.

Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Wednesday, November 7...

Navidea Biopharmaceuticals Wins Dismissal Of Platinum Litigation

Navidea Biopharmaceuticals Wins Dismissal Of Platinum Litigation

On October 31, 2018, Judge Valerie Caproni of the United States District Court for the Southern District of New York entered an Opinion and Order, as well as a Judgment, dismissing all claims raised by Platinum-Montaur Life Sciences LLC...

TheStreet Quant Rating: D- (Sell)